ClinicalTrials.gg
RecruitingNCT06131255DRACULA 1Updated Nov 12, 2026

Post-partum Depression: an Integrated Molecular-pharmaco-imaging Study

An observational study in Post-partum Depression, sponsored by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico. Recruiting at 1 site in Italy. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Observational

How we know · 4 judgments

From the registry’s dates

  • Started Aug 2023; still recruiting 3 years 3 months later.
Updated Nov 12, 2026Now RecruitingStart date moved+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
15
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

Post-partum depression (PPD) is a prevalent subtype of major depressive disorder that causes a significant distress to the woman and substantial impact on the whole family. Many studies implicate the glutamatergic system in pathological processes relevant to PPD disorders. There is evidence that cell adhesion molecules (CAMs) play a key role in how glutamatergic circuits wire up during development and how glutamatergic synapses, once formed, operate. However, it is unclear how dysregulation in diverse CAMs alter glutamatergic circuitries responsible for emotional and social behavior.

Here, the investigators propose to evaluate the molecular and neurobiological underpinnings of PPD focusing on CAMs at glutamatergic synapses by using an integrated approach from mouse models to human patients. Moreover, the investigators will also perform a pilot study to investigate the impact of selective antidepressants, known to be linked to CAMs, in both human and mice.

Read the detailed description

Patients will be recruited by the physician in charge of the study or collaborators of the S.C. Neonatology and Neonatal Intensive Care Unit of the IRCCS Ca' Granda Ospedale Maggiore Policlinico Foundation upon referral from the S.C. Psychiatry of the same institution. In the study, exposure to citalopram treatment will be 12 weeks with follow-up every 4 weeks. At each participant, at the time of enrollment, will be assigned a unique code so that only the local investigators can trace the subject's identity. As part of a scheduled visit to assess the clinical diagnosis, the PPD patient will be offered to participate in the study, after the appropriate signing of informed consent, the verification of absence of criteria for exclusion and existence of the study inclusion criteria. If these criteria are met, some demographic and clinical medical history of the women with PPD will be collected, as already provided by clinical practice for the management of the disease. Patients will undergo MRI scanning at baseline at the S.C. Neuroradiology of the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico and will begin the pharmacological treatment with citalopram. It is emphasized that the administration of citalopram therapy for the treatment of depressive symptomatology will be proposed and carried out in the patient due to clinical needs, based on the judgment of the competent physician and as would already be the case in practice, thus completely independent of participation or non-participation in the present study. Neuroimaging data will be obtained with a Philips 3T magnetic resonance imaging MRI machine. For each patient enrolled in the study, a structural T1 sequence (3D MPRAGE) is acquired.

T1-weighted MRI images will be used to study the differences brain morphology, including the volumes of gray matter (GM) and white matter (WM) and voxel-based morphometry. In a comparison parallel between regions of interest (ROIs), regional volumes will be estimated using the automated anatomical labeling atlas (AAL) as a reference, with emphasis on the dorsolateral PFC (DL)/ventrolateral (VL), cingulate cortex, amygdala and hippocampus. Further regional analysis will allow estimation, in addition to cortical volumes and subcortical volumes, cortical thickness, cortical surface area, and the cortical gyrification of the Desikan-Killiany atlas regions. During treatment with citalopram, patients will be visited, as per standard clinical practice, every 4 weeks. At each of these follow-up visits will be administered to patients by medical specialists the Brief Psychiatric Rating Scale (BPRS) and the Hamilton Depression Rating Scale (HAM- D) to study symptomatology depression. Patients will be, instead, self-administered in Italian language the Maternal Postnatal Attachment Scale (MPAS) and the Parental Stress Index (PSI) to investigate mother-child attachment and parental stress. The time scheduled for completion of both scales will be about 40 minutes. At 12 weeks, as per practice, the MRI scan will be repeated at the S.C. Neuroradiology Department of the Foundation. The following variables will be collected as part of this study: socio-demographic variables (age, schooling, socio-economic);

  • clinical/anamnestic variables (age of onset, duration of untreated treated, drug therapy, comorbidities, familiarity, substance abuse/dependence);
  • BPRS and HAM-D scales scores for symptomatology assessment (T0, T1, T2, T3);
  • MPAS and PSI scales scores for the assessment of mothers child attachment. (T0, T1, T2, T3);
  • MRI scan data (T0, T3): the images will be used to study brain morphological differences, including GM and WM volumes, and voxel-based morphometry. In a parallel comparison between regions of interest (ROI), regional volumes will be estimated using as a reference the automated anatomical labeling atlas (AAL), with particular attention to the dorsolateral (DL)/ventrolateral (VL) PFC, cingulate cortex, amygdala and hippocampus. A further regional analysis will make it possible to estimate, in addition to cortical and subcortical volumes, the thickness cortical, cortical surface area and cortical gyrification of the Desikan-Killiany atlas regions.
02

Conditions studied

  • Post-partum Depression

Keywords

  • post-partum depression
  • glutamatergic neurotransmission
  • antidepressants
  • citalopram
03

In context

Depression, Postpartum

570 studies on the registry are indexed under Depression, Postpartum; 135 are open to participants now.

This study's planned enrollment of 15 is below the median of 223 across 100 observational studies indexed under Depression, Postpartum.

Browse Depression, Postpartum studies →

Lead sponsor

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico is the lead sponsor of 237 studies on the registry; 81 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Women, aged 18 years to 40 years of age or older, with PPD who will be enrolled by the S.C. Neonatology and Neonatal Intensive Care Unit of the IRCCS Ca' Granda Ospedale Maggiore Policlinico Foundation upon referral from the S.C. Psychiatry of the same institution.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 40 years;
  • female gender;
  • PPD diagnosed by structured clinical interview support (SCID-5) by trained medical personnel;
  • comorbidity with metabolic syndrome, which can lead to brain damage and cognitive flaws;
  • need to start citalopram therapy for clinical needs (and therefore independent of study participation) or already on therapy for no more than two weeks;
  • moderate to severe depression according to the 17-item HAM-D (score 14-24);
  • absence of disabling medical and/or neurological conditions, including heart attacks, brain injuries, neurodegenerative diseases, head trauma with loss of consciousness for more than 30 minutes;
  • Absence of concomitant psychiatric therapies (antidepressants, antipsychotics of the first and second generation and mood stabilizers);
  • absence of for MRI scanning;
  • patients who have signed .

Exclusion criteria

Exclusion Criteria:

  • age below 18 years or above 40 years;
  • diagnosis different from PPD based on SCID-5;
  • absence of metabolic syndrome;
  • low depression according to the 17-item HAM-D (score less than 14);
  • presence of disabling medical and/or neurological conditions, including heart attacks, brain injuries, neurodegenerative diseases, head trauma with loss of consciousness for more than 30 minutes;
  • presence of concomitant drug therapies (antidepressants, first- and second-generation antipsychotics and mood stabilizers);
  • presence of for MRI scanning;
  • presence of contraindications for citalopram;
  • patients who have not signed .
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
15 participants (estimated)
Patient registry
No

Groups and cohorts

  • Women with Post-Partum Depression

    15 women with PPD referred to the S.C. Psychiatry of IRCCS Ca' Granda Ospedale Maggiore Policlinico Foundation and referred to the S.C. Neonatology and Neonatal Intensive Care Unit of the same institution for enrollment.

    Drug: Citalopram

Interventions

  • Patients will be administered citalopram, regardless of inclusion or non-inclusion in this study, on medical indication, as per normal clinical practice for disease management and according to the Summary of Product Characteristics (SPC). Patients will have two MRI scans done (at baseline and at 12 weeks after the start of therapy) to assess: brain volumetry, tissue amount of gray matter - GM - and white matter - WM

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Total White Matter (WM) Volume at Week 12

    Total white matter volume, expressed in cubic millimeters (mm³), will be estimated from 3D T1-weighted (MPRAGE) images acquired on a Philips 3T MRI scanner, using tissue segmentation in SPM12 (voxel-based morphometry). A single value per participant (total WM volume) will be computed at each time point, and the change from baseline (week 12 minus baseline) will be reported.

    Time frame: Baseline and week 12

  2. Change From Baseline in Total Gray Matter (GM) Volume at Week 12

    Total gray matter volume, expressed in cubic millimeters (mm³), will be estimated from 3D T1-weighted (MPRAGE) images acquired on a Philips 3T MRI scanner, using tissue segmentation in SPM12 (voxel-based morphometry). A single value per participant (total GM volume) will be computed at each time point, and the change from baseline (week 12 minus baseline) will be reported.

    Time frame: Baseline and week 12

  3. Change From Baseline in Total Brain Volume at Week 12

    Total brain volume, expressed in cubic millimeters (mm³), will be calculated as the sum of total gray matter and total white matter volumes obtained from SPM12 segmentation of 3D T1-weighted (MPRAGE) images acquired on a Philips 3T MRI scanner. A single value per participant will be computed at each time point, and the change from baseline (week 12 minus baseline) will be reported.

    Time frame: Baseline and week 12

Secondary outcomes

  1. Change From Baseline in Hamilton Depression Rating Scale (HAM-D, 21-item) Total Score at Week 12

    Depressive symptom severity will be assessed with the clinician-administered 21-item Hamilton Depression Rating Scale (HAM-D). Higher scores indicate more severe depression. The change from baseline (week 12 minus baseline) in total score will be reported.

    Time frame: Baseline and week 12

  2. Percentage of Participants Responding to Treatment at Week 12

    Response is defined as a reduction of at least 30% in the 21-item Hamilton Depression Rating Scale (HAM-D) total score at week 12 compared with baseline. Higher HAM-D scores indicate more severe depression. The percentage of participants meeting the response criterion will be reported.

    Time frame: Baseline and week 12

Other outcomes

  1. Number of Participants With Adverse Events Related to Citalopram

    Number of participants experiencing at least one serious or non-serious adverse event judged by the medical staff to be related to citalopram, from treatment start through week 12.

    Time frame: From baseline through week 12

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Asahina H, Masuba A, Hirano S, Yuri K. Distribution of protocadherin 9 protein in the developing mouse nervous system. Neuroscience. 2012 Dec 6;225:88-104. doi: 10.1016/j.neuroscience.2012.09.006. Epub 2012 Sep 11. PubMed 22982106 ↗
  • Bambico FR, Belzung C. Novel insights into depression and antidepressants: a synergy between synaptogenesis and neurogenesis? Curr Top Behav Neurosci. 2013;15:243-91. doi: 10.1007/7854_2012_234. PubMed 23271325 ↗
  • Boku S, Nakagawa S, Toda H, Hishimoto A. Neural basis of major depressive disorder: Beyond monoamine hypothesis. Psychiatry Clin Neurosci. 2018 Jan;72(1):3-12. doi: 10.1111/pcn.12604. Epub 2017 Oct 19. PubMed 28926161 ↗
  • Bruining H, Matsui A, Oguro-Ando A, Kahn RS, Van't Spijker HM, Akkermans G, Stiedl O, van Engeland H, Koopmans B, van Lith HA, Oppelaar H, Tieland L, Nonkes LJ, Yagi T, Kaneko R, Burbach JP, Yamamoto N, Kas MJ. Genetic Mapping in Mice Reveals the Involvement of Pcdh9 in Long-Term Social and Object Recognition and Sensorimotor Development. Biol Psychiatry. 2015 Oct 1;78(7):485-95. doi: 10.1016/j.biopsych.2015.01.017. Epub 2015 Feb 7. PubMed 25802080 ↗
  • Cingolani LA, Thalhammer A, Yu LM, Catalano M, Ramos T, Colicos MA, Goda Y. Activity-dependent regulation of synaptic AMPA receptor composition and abundance by beta3 integrins. Neuron. 2008 Jun 12;58(5):749-62. doi: 10.1016/j.neuron.2008.04.011. PubMed 18549786 ↗
  • Davis AD, Hassel S, Arnott SR, Harris J, Lam RW, Milev R, Rotzinger S, Zamyadi M, Frey BN, Minuzzi L, Strother SC, MacQueen GM, Kennedy SH, Hall GB. White Matter Indices of Medication Response in Major Depression: A Diffusion Tensor Imaging Study. Biol Psychiatry Cogn Neurosci Neuroimaging. 2019 Oct;4(10):913-924. doi: 10.1016/j.bpsc.2019.05.016. Epub 2019 Jun 12. PubMed 31471185 ↗
  • Postpartum Depression: Action Towards Causes and Treatment (PACT) Consortium. Heterogeneity of postpartum depression: a latent class analysis. Lancet Psychiatry. 2015 Jan;2(1):59-67. doi: 10.1016/S2215-0366(14)00055-8. Epub 2015 Jan 8. PubMed 26359613 ↗
  • Duric V, Banasr M, Stockmeier CA, Simen AA, Newton SS, Overholser JC, Jurjus GJ, Dieter L, Duman RS. Altered expression of synapse and glutamate related genes in post-mortem hippocampus of depressed subjects. Int J Neuropsychopharmacol. 2013 Feb;16(1):69-82. doi: 10.1017/S1461145712000016. Epub 2012 Feb 17. PubMed 22339950 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Jan 2027, 41 months after the start.

Of 51 non-industry observational studies under Depression, Postpartum, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 52. This study's planned 41 months is above that.

Counting every sponsor, half of 53 studies reached it within 25 months; a quarter within 6 and three quarters within 52.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: start Jan 2024 → Aug 2023, primary completion Dec 2025 → Jan 2027 and completion Apr 2026 → Jul 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2023
First posted
Nov 14, 2023
StartActual
Aug 1, 2023was Jan 2024
Primary completionEst.
Jan 2027was Dec 2025
CompletionEst.
Jul 2027was Apr 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 12, 2026
Sites
1 site added, 1 site removed
Show site
  • Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico · Milan, Italy
Show 1 removed
  • Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico · Milan, Italy
Nov 12, 2026
Start date
Jan 1, 2024→Aug 1, 2023 (actual)
Nov 12, 2026
Primary completion
Dec 1, 2025→Jan 2027
Nov 12, 2026
Study completion
Apr 30, 2026→Jul 2027
Nov 12, 2026
Primary outcomes
3 added, 2 removed
What changed in the outcomes
  • AddedChange From Baseline in Total White Matter (WM) Volume at Week 12Time frame: Baseline and week 12
  • AddedChange From Baseline in Total Gray Matter (GM) Volume at Week 12Time frame: Baseline and week 12
  • AddedChange From Baseline in Total Brain Volume at Week 12Time frame: Baseline and week 12
  • RemovedEvaluate the citalopram effect on white matter morphologyTime frame: 12 weeks
  • RemovedEvaluate the citalopram effect on gray matter morphologyTime frame: 12 weeks
Nov 12, 2026
Secondary outcomes
1 edited, 2 added, 1 removed
What changed in the outcomes
  • AddedChange From Baseline in Hamilton Depression Rating Scale (HAM-D, 21-item) Total Score at Week 12Time frame: Baseline and week 12
  • AddedPercentage of Participants Responding to Treatment at Week 12Time frame: Baseline and week 12
  • RemovedTo evaluate the efficacy of citalopram on the clinical symptomatology of the PPD patients through the use of clinical scalesTime frame: 12 weeks
  • Changedother outcomeBefore Assess the tolerability profile of the drug in the same patientsNow Number of Participants With Adverse Events Related to CitalopramTime frame: 12 weeks → From baseline through week 12
Nov 12, 2026
Title
DRACULA1 PartumPost-partum Depression: an Integrated Molecular-pharmaco-imaging Study")
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Not yet recruiting→Recruiting
    1 site added, 1 site removed
    Show site
    • Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico · Milan, Italy
    Show 1 removed
    • Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico · Milan, Italy
    Start date Jan 1, 2024→Aug 1, 2023 (now actual)
    Primary completion Dec 1, 2025→Jan 2027
    Study completion Apr 30, 2026→Jul 2027
    Primary outcomes 3 added, 2 removed
    What changed in the outcomes
    • AddedChange From Baseline in Total White Matter (WM) Volume at Week 12Time frame: Baseline and week 12
    • AddedChange From Baseline in Total Gray Matter (GM) Volume at Week 12Time frame: Baseline and week 12
    • AddedChange From Baseline in Total Brain Volume at Week 12Time frame: Baseline and week 12
    • RemovedEvaluate the citalopram effect on white matter morphologyTime frame: 12 weeks
    • RemovedEvaluate the citalopram effect on gray matter morphologyTime frame: 12 weeks
    Secondary outcomes 1 edited, 2 added, 1 removed
    What changed in the outcomes
    • AddedChange From Baseline in Hamilton Depression Rating Scale (HAM-D, 21-item) Total Score at Week 12Time frame: Baseline and week 12
    • AddedPercentage of Participants Responding to Treatment at Week 12Time frame: Baseline and week 12
    • RemovedTo evaluate the efficacy of citalopram on the clinical symptomatology of the PPD patients through the use of clinical scalesTime frame: 12 weeks
    • Changedother outcomeBefore Assess the tolerability profile of the drug in the same patientsNow Number of Participants With Adverse Events Related to CitalopramTime frame: 12 weeks → From baseline through week 12
    Title DRACULA1 PartumPost-partum Depression: an Integrated Molecular-pharmaco-imaging Study")
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06131255
Responsible party
Sponsor
First posted
Nov 14, 2023
Start date
Aug 1, 2023
Primary completion
Jan 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Domenica mercadante, doctor
Contact
domenica.mercadante@policlinico.mi.it
02 5503 2234

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion